[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 sale 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
검색광고안내
랩노트
스폰서배너광고 안내  배너1 배너2 배너3 배너4
과학으로 본 코로나19 (COVID-19)
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
이승헌
이승헌 (Seung Heon Lee) 저자 이메일 보기
고려대학교 안산병원
저자CV 보기
123 KB
 
조회 1033  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis

Won-Jung Koh1*, Seung Heon Lee2*, Young Ae Kang3, Chang-Hoon Lee4, Jae Chol Choi5, Jae Ho Lee6, Seung Hun Jang7, Kwang Ha Yoo8, Ki Hwan Jung2, Ki Uk Kim9, Sang Bong Choi10, Yon Ju Ryu11, Kyung Chan Kim12, Soojung Um13, Yong Soo Kwon14, Yee Hyung Kim15, Won-Il Choi16, Kyeongman Jeon1, Yong Il Hwang7, Se Joong Kim2, Young Seok Lee17, Eun Young Heo4, Juhee Lee18, Yeo Woon Ki19, Tae Sun Shim20, and Jae-Joon Yim19

1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
2Division of Pulmonary, Sleep and Critical Care Medicine, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Republic of Korea
3Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
4Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea
5Department of Internal Medicine, Chung-Ang University School of Medicine, Seoul, Republic of Korea
6Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Republic of Korea
7Division of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Gyeonggi-do, Republic of Korea
8Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Republic of Korea
9Department of Internal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea
10Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea
11Division of Pulmonary and Critical Care Medicine, Department of Medicine, Ewha Medical Center and Ewha Medical Research Institute, Ewha Womans University School of Medicine, Mokdong Hospital, Seoul, Republic of Korea
12Department of Internal Medicine, Catholic University of Daegu Hospital, Daegu, Republic of Korea
13Department of Internal Medicine, Division of Respirology, Dong-A University Medical Center, Busan, Republic of Korea
14Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea
15Department of Pulmonary and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, Seoul, Republic of Korea
16Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea
17Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Busan Paik Hospital Inje University College of Medicine, Busan, Republic of Korea
18Medical Research Collaborating Center and
19Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea; and
20Division of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea

Abstract
Rationale: Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB). However, studies comparing the effectiveness of LFX and MXF among patients with MDR-TB are lacking.

Objectives: To compare the effectiveness of LFX and MXF in terms of culture conversion after 3 months of treatment for MDR-TB.

Methods: In this prospective multicenter randomized open label trial, we randomly assigned 182 patients with MDR-TB (sensitive to LFX and MXF) to receive either LFX (750 mg/day; 90 patients) or MXF (400 mg/day; 92 patients) with a background drug regimen. The primary outcome was the proportion of patients who achieved sputum culture conversion at 3 months of treatment. Secondary outcomes were time to culture conversion and time to smear conversion, with data censored at 3 months, and the proportions of adverse drug reactions.

Measurements and Main Results: At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in the MXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27-2.20). Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in the MXF group (P = 0.75).

Conclusions: The choice of LFX or MXF for treatment of patients with MDR-TB may not affect sputum culture conversion at 3 months of treatment.

KEYWORDS: multidrug-resistant tuberculosis, fluoroquinolone, moxifloxacin, levofloxacin

Correspondence and requests for reprints should be addressed to Jae-Joon Yim, M.D., Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea.
*W.-J.K. and S.H.L. contributed equally to this work.

논문정보
- 형식: Research article
- 게재일: 2013년 10월 (BRIC 등록일 2013-10-02)
- 연구진: 국내연구진태극기
- 분야: Medicine
Dot/Icm 제 4 유형 커플링 단백질 복합체의 선택적 이펙터 단백질 인식[Nat. Commun.]
김현민
발표: 김현민 (KAIST)
일자: 2020년 9월 29일 (화) 오후 02시 (한국시간)
언어: 한국어
참석자 접수신청하기

  댓글 0
등록
 
목록
메틀러 토레도
관련링크
이승헌 님 전체논문보기 >
관련인물
관련분야 논문보기
Medicine

외부링크
Google (by Seung Heon Lee)
Pubmed (by Seung Heon Lee)
프리미엄 Bio일정 Bio일정 프리미엄 안내
대구경북과학기술원 (DGIST) 뇌·인지과학전공 온라인 전공설명회 개최
위로가기
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS
에펜도르프코리아 광고